Cardiology Research and Practice / 2019 / Article / Tab 6 / Research Article
Predictors of Unfavorable Outcomes in Patients with Atrial Fibrillation and Concomitant Heart Failure with Different Ejection Fractions: RIF-CHF Register One-Year Follow-Up Table 6 Univariate regression logistic analysis of the risk of hospitalization due to decompensation of HF.
Group of factors Factor AF-HFpEF AF-HFmrEF AF-HFrEF OR (2.5–97.5) OR (2.5–97.5) OR (2.5–97.5) Laboratory tests LDH 1.007 (1.004–1.011) <0.001 Total bilirubin 1.035 (1.005–1.07) 0.031 Kreatinin 1.008 (1.002–1.014) 0.01 Demography Age > 65 years 2.329 (1.462–3.745) <0.001 1.736 (1.17–2.584) 0.006 Female gender 1.866 (1.198–2.921) 0.006 Habits and lifestyle Smoking (ever) 1.852 (1.073–3.236) 0.028 Bad habits 2.009 (1.107–3.723) 0.023 Alcohol usage history 1.37 (1.038–1.828) 0.028 Level of physical activity 0.549 (0.274–1.081) 0.085 0.616 (0.399–0.944) 0.027 Symptoms and syndromes The number of specific signs of HF 1.482 (1.146–1.946) 0.003 Increase of venous pressure 2.383 (1.02–5.847) 0.048 The number of typical symptoms of HF 2.275 (1.1–4.844) 0.028 Concomitant diseases Diabetes mellitus 1.733 (1.048–2.908) 0.034 CV system characteristics Arterial hypertension 2.347 (1.524–3.663) <0.001 Duration of arterial hypertension 1.03 (1.002–1.061) 0.044 Degree of tricuspid insufficiency 1.408 (1.027–1.949) 0.036 Degree of aortal insufficiency 1.721 (1.074–2.865) 0.028 Degree of pulmonary insufficiency 3.69 (1.46–10.87) 0.01 Mitral insufficiency 1.543 (0.937–2.54) 0.087 Hemodynamically significant coronary artery stenosis 2.166 (1.276–3.8) 0.005 Cardiothoracic index (%) 1.138 (1.047–1.244) 0.003 Vascular disease 1.73 (1.126–2.673) 0.013 Prior stroke or TIA or thromboembolism 1.866 (1.198–2.921) 0.006 Therapy Regular use of antiarrhythmic drugs 0.622 (0.393–0.978) 0.041 Regular use of ACE inhibitors 0.582 (0.371–0.907) 0.017 Permanent AF therapy with calcium channel blockers 0.505 (0.311–0.812) 0.005 Regular use of angiotensin II receptor blocker 0.466 (0.288–0.745) 0.002 0.587 (0.331–1.01) 0.06 Regular use of anticoagulants 0.389 (0.257–0.587) <0.001 Permanent AF therapy with beta-blockers 0.279 (0.152–0.496) <0.001 Rational therapy of HF 0.409 (0.271–0.611) <0.001 Regular use of aldosterone antagonist 0.584 (0.361–0.942) 0.027 Regular use of NOAC 0.588 (0.377–0.907) 0.017 Rate control strategy (versus rhythm control strategy) 1.779 (1.156–2.747) 0.009 0.283 (0.125–0.599) 0.001 AF/HF features HF developed after AF debut 2.002 (1.049–3.879) 0.037 AF duration 1.005 (1.001–1.01) 0.022 HF duration 1.005 (1.002–1.009) 0.003 EF 0.958 (0.922–0.995) 0.026 Persistent form of AF (versus paroxysmal form) 0.464 (0.296–0.722 0.001 2.755 (1.451–5.405) 0.002 Scales and risks CHA2DS2-VASc 1.393 (1.215–1.608) <0.001 1.191 (0.981–1.46) 0.083 1.215 (1.089–1.359) 0.001 HAS-BLED 1.461 (1.174–1.836) 0.001 1.196 (1.014–1.414) 0.035
